We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

By LabMedica International staff writers
Posted on 05 Jul 2015
Print article
A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers.

The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived from research performed in the laboratory of Dr. Sabine Brouxhon, associate professor of emergency medicine at Stony Brook University.

Dr. Brouxhon's approach is based on antibodies that target soluble E-cadherin. Soluble E-cadherin levels have been shown to be elevated in the microenvirnoment of many solid tumors and contribute to enhanced tumor cell proliferation, migration, and invasion, which is linked to metastatic disease.

“One of the most significant drawbacks from current cancer treatments is that despite their initial effectiveness against solid tumors, patients often develop resistance to these treatments,” said Dr. Brouxhon. “Our lab has discovered a novel antibody-based cancer therapy that acts through a completely different mechanism of action compared to existing drugs in industry. Notably, the antibody down-regulates multiple resistant pathways, thereby minimizing the cancer cells ability to recruit many interconnected oncogenes that are linked with resistant disease.”

Under terms of the licensing agreement CadheRx Therapeutics will create targeted antibody agents to counter de novo or acquired resistance. The company is financially backed by Avalon Ventures (La Jolla, CA, USA) and is one of six startup companies formed from collaboration between Avalon Ventures and GlaxoSmithKline (London, United Kingdom) that began in April 2013.

“It is extraordinarily exciting to see a basic research discovery from a Stony Brook University scientist turn into something that might improve people’s lives in a very powerful way,” said Dr. Samuel L. Stanley Jr., president of Stony Brook University. “Cancer affects millions of people worldwide, and Dr. Brouxhon’s work on this new anticancer technology offers continued hope in the fight against many forms of cancer.”

Related Links:

Stony Brook University
Avalon Ventures
GlaxoSmithKline


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Unit-Dose Packaging solution
HLX
New
Urine Drug Test
Instant-view Methadone Urine Drug Test
New
Monkeypox Test
Monkeypox Virus Rapid Antibody Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.